Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary

Achieved a defining milestone of financial self-sustainability, effectively removing the need for external funding to support the current strategy and pipeline. Recorlev served as the primary growth engine, nearly doubling its patient base to approximately 700 patients by year-end 2025. Gvoke provided durable and predictable revenue growth of 14% for the full year, supported by broad market access and alignment with treatment guidelines. Keveyis outperformed expectations by increasing the average nu ...